Managed Entry Agreements for new medicines in the Baltic countries

Diāna Arāja, Keili Kõlves

Research output: Contribution to specialist publicationSpecialist article


Managed entry agreements (MEAs) have become a topical issue due to the increasing cost of new medicines and the presence of significant uncertainty at the time of making reimbursement decisions. There are uncertainties about clinical and economic evidence, fair prices and budget impact, as well as about the eligible patient population. Innovative solutions are needed to make new medicines
available to patients and to ensure the long-term financial sustainability of health care systems. This article outlines the use of MEAs in Estonia, Latvia and Lithuania as part of their pharmaceutical policy arsenal to improve access to new medicines.
Original languageEnglish
Number of pages4
Specialist publicationEurohealth
PublisherRegional Office for Europe, World Health Organization
Publication statusPublished - 2016
Externally publishedYes


  • Managed Entry Agreements, Reimbursement, Pharmaceutical Policy, Estonia, Latvia, Lithuania

Field of Science*

  • 3.3 Health sciences

Publication Type*

  • 6. Other publications


Dive into the research topics of 'Managed Entry Agreements for new medicines in the Baltic countries'. Together they form a unique fingerprint.

Cite this